bioAffinity Technologies (NASDAQ:BIAF) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of bioAffinity Technologies (NASDAQ:BIAF) from a sell rating to a hold rating in a research note issued to investors on Monday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Monday, July 20th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, bioAffinity Technologies currently has an average rating of “Sell”.

bioAffinity Technologies Stock Performance

NASDAQ BIAF opened at $0.47 on Monday. The company has a quick ratio of 1.34, a current ratio of 1.36 and a debt-to-equity ratio of 0.15. bioAffinity Technologies has a 52-week low of $0.46 and a 52-week high of $13.50. The business’s 50-day moving average price is $0.86 and its 200 day moving average price is $1.62. The firm has a market cap of $2.24 million, a P/E ratio of -0.06 and a beta of -1.05.

bioAffinity Technologies (NASDAQ:BIAF) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($2.10) by $1.46. bioAffinity Technologies had a negative return on equity of 196.80% and a negative net margin of 257.30%.The firm had revenue of $1.51 million during the quarter, compared to the consensus estimate of $1.70 million.

Institutional Investors Weigh In On bioAffinity Technologies

Several institutional investors have recently made changes to their positions in BIAF. Geode Capital Management LLC acquired a new position in shares of bioAffinity Technologies during the 4th quarter worth $36,000. Scientech Research LLC acquired a new stake in shares of bioAffinity Technologies in the third quarter valued at about $49,000. Finally, J. Safra Sarasin Holding AG purchased a new stake in bioAffinity Technologies during the first quarter worth about $164,000. 1.64% of the stock is currently owned by hedge funds and other institutional investors.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.